Ê÷ͻ״ϸ°ûÓÕµ¼µÄCTLsÓëCIK¼°LAKϸ°û¶ÔÉñ¾­½ºÖÊÁöɱÉË×÷ÓñȽÏ

¡¡¡¡[3] GABRILOVICH D I, CIEMIK I F, CARBONE D P. Dendriª²tic cells in antitumor immune response.¢ñ. Defective antigen presentation in tumorª²bearing host[J]. Cell Immunol, 1996,170:101.

¡¡¡¡[4] SCHMIDª²WOLF I G H, NEGRIN R S. Phenotypic characteª²rization and identification of effecter cells involved in tumor cell recognition of cytokine induced killer cells[J]. Exp Hematol, 1993, 21: 1673.

¡¡¡¡[5] TAKAHASHI H, NAKADA T, PUSIEUX I. Inhibition of human colon cancer growth by antibodyª²directed human LAK cells in SCID mice[J]. Science, 1993,259:1460.

¡¡¡¡[6] SCHMIDª²WOLF I G H, NEGRIN R S, KIEM H, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokineª²induced killer cells with potent antitumor cell activity[J]. J Exp Med, 1991,174:139.

¡¡¡¡[7] HSU F, BENIKE C, FAGNONI F, et al. Vaccination of patients with Bª²cell lymphoma using autologous antigenª²pulsed dendritic cells[J]. Nat Med, 1996,36(2):52.

¡¡¡¡[8] KRAUSE S W, NEUMANN C, SORURI A, et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells[J]. Immunother, 2002,25(5):421.

¡¡¡¡[9] TJOA B A, SIMMONS S J, BOWES V A, et al. Evaluation of Phase ¢ñ/¢ò clinical trials in prostate cancer with dendritic cells and PSMA peptides[J]. Prostate£¬ 1998,36(6): 39.

ÉÏÒ»Ò³  [1] [2] [3] [4]